Table 2.
Concomitant non-OAB medications relevant to cognition during double-blind treatment period
| n (%) | Placebo (n = 442) | Mirabegron Total (n = 445) |
|---|---|---|
| CONCOMITANT ANTIDEPRESSANTS | ||
| SSRIs | 54 (12.2) | 53 (11.9) |
| Citalopram | 14 (3.2) | 9 (2.0) |
| Sertraline | 11 (2.5) | 4 (0.9) |
| Escitalopram oxalate | 5 (1.1) | 8 (1.8) |
| Escitalopram | 5 (1.1) | 7 (1.6) |
| Fluoxetine | 8 (1.8) | 4 (0.9) |
| Citalopram hydrobromide | 3 (0.7) | 6 (1.3) |
| Paroxetine | 1 (0.2) | 6 (1.3) |
| Sertraline hydrochloride | 4 (0.9) | 3 (0.7) |
| Fluoxetine hydrochloride | 3 (0.7) | 3 (0.7) |
| Paroxetine hydrochloride | 0 | 3 (0.7) |
| Other antidepressants | 23 (5.2) | 31 (7.0) |
| Trazodone | 13 (2.9) | 17 (3.8) |
| Duloxetine | 3 (0.7) | 4 (0.9) |
| Duloxetine hydrochloride | 4 (0.9) | 2 (0.4) |
| Mirtazapine | 2 (0.5) | 3 (0.7) |
| Trazodone hydrochloride | 0 | 3 (0.7) |
| Venlafaxine hydrochloride | 2 (0.5) | 1 (0.2) |
| Desvenlafaxine succinate | 0 | 1 (0.2) |
| Nefazodone | 0 | 1 (0.2) |
| Oxitriptan | 0 | 1 (0.2) |
| Venlafaxine | 1 (0.2) | 0 |
| Vortioxetine | 1 (0.2) | 0 |
| Non-selective monoamine reuptake inhibitors | 7 (1.6) | 9 (2.0) |
| Amitriptyline | 2 (0.5) | 7 (1.6) |
| Doxepin | 1 (0.2) | 1 (0.2) |
| Nortriptyline | 2 (0.5) | 0 |
| Amitriptyline hydrochloride | 0 | 1 (0.2) |
| Imipramine | 1 (0.2) | 0 |
| Nortriptyline hydrochloride | 1 (0.2) | 0 |
| Diazepines, oxazepines, thiazepines and oxepines | 3 (0.7) | 1 (0.2) |
| Quetiapine fumarate | 3 (0.7) | 1 (0.2) |
| Other antipsychotics | 0 | 2 (0.4) |
| Aripiprazole | 0 | 1 (0.2) |
| Risperidone | 0 | 1 (0.2) |
| CONCOMITANT ANTICHOLINERGICS | ||
| Antihistamines for systemic use | 38 (8.6) | 41 (9.2) |
| Hydroxyzine | 2 (0.5) | 2 (0.4) |
| Hydroxyzine hydrochloride | 1 (0.2) | 1 (0.2) |
| Aminoalkyl ethers | 15 (3.4) | 16 (3.6) |
| Diphenhydramine hydrochloride | 10 (2.3) | 11 (2.5) |
| Diphenhydramine | 4 (0.9) | 4 (0.9) |
| Dimenhydrinate | 1 (0.2) | 1 (0.2) |
| Carbinoxamine maleate | 0 | 1 (0.2) |
| Piperazine derivatives | 3 (0.7) | 2 (0.4) |
| Meclozine | 2 (0.5) | 1 (0.2) |
| Phenothiazine derivatives | 1 (0.2) | 1 (0.2) |
| Promethazine | 1 (0.2) | 0 |
| Promethazine hydrochloride | 0 | 1 (0.2) |
| Substituted alkylamines | 0 | 2 (0.4) |
| Chlorphenamine maleate | 0 | 2 (0.4) |
| Cough and cold preparations | 17 (3.8) | 20 (4.5) |
| Promethazine with codeine | 0 | 1 (0.2) |
| Carbamic acid esters | 5 (1.1) | 1 (0.2) |
| Carisoprodol | 2 (0.5) | 1 (0.2) |
| Synthetic anticholinergics, esters with tertiary amine groups | 0 | 2 (0.4) |
| Dicycloverine hydrochloride | 0 | 2 (0.4) |
OAB overactive bladder, SSRIs selective serotonin reuptake inhibitors